[US Stocks Alert] Kailera Therapeutics soars on October 9th: Phase III enrollment completed, clinical data released, and obesity drug progress
Bitget异动解读2026/10/09 15:25Kailera Therapeutics October 9 Surge Interpretation
Keywords: phase 3 enrollment completion, clinical data, obesity drugs
1. On September 30, the company announced the global KaiNETIC phase 3 project had completed enrollment, covering 3 trials and over 200 research centers. The primary objective is to evaluate weekly injections of the GLP-1/GIP dual receptor agonist lirupatide, with top-line data expected to be released in mid-2028.
2. On October 1, the company presented phase 1 data on lirupatide injection at the EASD 2026 conference. Among 51 trial participants, drug exposure levels after injections in the upper arm or thigh were similar to those after abdominal injections, and no new safety signals were observed. Additionally, the company’s partners submitted four relevant oral presentations.
(Disclaimer: This content is summarized and generated from publicly available information by AI technology. It is for reference only and does not constitute investment advice.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
U.S. stocks move | Moderna (MRNA.US) rises 7% after being included in the Nasdaq 100 Index
According to information from Zhihui Finance APP, on Friday, Moderna (MRNA.US) surged as much as 10% during trading, reaching its highest share price since December 2022. As of press time, the gain narrowed to 7%, with the stock trading at $210.95. On the news front, on October 9, Moderna was officially included in the Nasdaq 100 index, replacing Warner Bros Discovery. After its inclusion, some broad-based institutions that previously did not allocate to biotech will now passively hold the stock, while active institutions will add the company to their watch lists, increasing attention on the individual stock.
Crypto prices
More
